3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High

Johnson & Johnson is presented as a long-term growth and income investment, supported by a broad drug pipeline, including Phase 3 multiple-myeloma candidate ramantamig with estimated peak annual sales of $1B-$5B. Its recently cleared Ottava robotic surgery system targets a largely underpenetrated market, with fewer than 8% of relevant soft-tissue procedures currently performed robotically. J&J has also raised its dividend for 64 consecutive years and offers a 2.0% forward yield versus the S&P 500 average of 1.1%, although drug competition and government price negotiations remain headwinds.

Analysis

JNJ’s rerating ceiling is likely governed less by pipeline breadth than by whether management can replace erosion in legacy immunology/oncology franchises without sacrificing operating margin. The relevant 1-3 month catalyst is not another early pipeline headline, but evidence in quarterly guidance that new-product contribution is offsetting price and biosimilar pressure faster than consensus expects. A sustained beat-and-raise cycle could support a defensive-quality multiple expansion; failure to lift organic growth despite launches would expose the stock as a low-growth yield proxy with limited upside near highs.

Ottava is strategically more important as a competitive option than a near-term earnings driver. ISRG’s installed base, surgeon training ecosystem, service relationships, and procedure-specific instrument pull-through create high switching costs, so initial JNJ placements may be incremental to robotic adoption rather than materially cannibalistic. Over 6-18 months, the key KPI is hospital utilization and recurring instrument revenue per installed system; discounted capital placements without consumable pull-through would dilute medtech margins and should not be rewarded.

The contrarian risk is that investors treat JNJ’s dividend profile as insulation from litigation, drug-pricing, and patent-loss volatility. Defensive ownership can unwind if cash deployment shifts toward settlements or if Medicare pricing pressure broadens beyond the market’s modeled products. Conversely, JNJ has a more credible path to upside than ISRG if Ottava adoption is merely adequate: JNJ’s valuation embeds modest medtech optionality, while ISRG requires continued premium procedure-growth execution to defend its multiple.

Key Decisions for Investors

• Maintain a modest long JNJ only on pullbacks rather than chase strength; target a 6-12 month hold. Add if management raises full-year operational sales or EPS guidance while reaffirming Innovative Medicine margin trajectory. Thesis is falsified by a guidance cut tied to price erosion, litigation cash outflow, or weaker-than-expected new-product uptake.
• Avoid a directional short in ISRG solely on Ottava. Instead, monitor ISRG’s procedure-growth rate, installed-base additions, and recurring revenue per system over the next 2-3 earnings reports; a sustained deceleration versus guidance would create a more credible relative-value setup.
• For a measured competitive-dynamics expression, consider long JNJ / short XLV in equal beta-adjusted dollars over 6-12 months only if Ottava placement disclosures and pharmaceutical guidance improve. The pair isolates JNJ-specific execution, but exit if Ottava commercialization requires meaningful discounting or JNJ’s organic growth falls below large-cap pharma peers.
• Set an alert around the first disclosed Ottava utilization and instrument-revenue metrics. Do not underwrite meaningful medtech EPS contribution until recurring procedure economics—not system-clearance or placement announcements—are independently visible.